• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

Philogen announces through its wholly-owned Swiss subsidiary, Philochem AG, a participation in the Eurostars Cut-off 8 Project (ComPAIR): “Comprehensive Prediction of Allogeneic Immune Response”

by last | Mar 1, 2019 | 2019, Press Releases

Philogen announces through its wholly-owned Swiss subsidiary, Philochem AG, a participation in the Eurostars Cut-off 8 Project (ComPAIR): “Comprehensive Prediction of Allogeneic Immune Response” ComPAIR

Philogen announces drug discovery collaboration with Johnson & Johnson Innovation

by last | Jan 23, 2019 | 2019, Press Releases

Philogen announces drug discovery collaboration with Johnson & Johnson Innovation

Philochem announces a publication entitled: “Quantitative Assessment of Affinity Selection Performance by Using DNA‐Encoded Chemical Libraries”

by last | Dec 13, 2018 | 2018, Press Releases

Link to Paper

Philochem will be attending the 8th World ADC Conference in San Diego

by last | Oct 1, 2018 | 2018, Press Releases

Philochem will be attending the 8th World ADC Conference in San Diego (United States) from November 12 to 15, 2018 8th World ADC San Diego Dr. Samuele Cazzamalli will give a presentation on: “Small ligands for the imaging and the treatment of solid tumors in...

Philochem will be attending the 8th International Symposium on DNA-Encoded Chemical Libraries in Chengdu

by last | Sep 1, 2018 | 2018, Press Releases

Philochem will be attending the 8th International Symposium on DNA-Encoded Chemical Libraries in Chengdu (China) from October 17 to 19, 2018 8th International Symposium on DNA-Encoded Chemical Libraries Philogen Co-founder Prof. Dr. Dario Neri will give a lecture...

Philochem will be attending the 25th EFMC Symposium in Ljubljana

by last | Aug 1, 2018 | 2018, Press Releases

Philochem will be attending the 25th EFMC Symposium in Ljubljana (Slovenia) from September 2 to 6, 2018 EFMC Ljubljana Dr. Etienne Donckele and Alessandro Sannino will present posters
« Older Entries
Next Entries »

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch